Your browser doesn't support javascript.
loading
Differential effects of fingolimod on B-cell populations in multiple sclerosis.
Nakamura, Masakazu; Matsuoka, Takako; Chihara, Norio; Miyake, Sachiko; Sato, Wakiro; Araki, Manabu; Okamoto, Tomoko; Lin, Youwei; Ogawa, Masafumi; Murata, Miho; Aranami, Toshimasa; Yamamura, Takashi.
Afiliação
  • Nakamura M; Department of Immunology, National Institute of Neuroscience, National Centre of Neurology and Psychiatry (NCNP), Tokyo, Japan Department of Neurology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Matsuoka T; Department of Immunology, National Institute of Neuroscience, National Centre of Neurology and Psychiatry (NCNP), Tokyo, Japan.
  • Chihara N; Department of Immunology, National Institute of Neuroscience, National Centre of Neurology and Psychiatry (NCNP), Tokyo, Japan.
  • Miyake S; Department of Immunology, National Institute of Neuroscience, National Centre of Neurology and Psychiatry (NCNP), Tokyo, Japan Multiple Sclerosis Centre, National Centre Hospital, NCNP, Tokyo, Japan.
  • Sato W; Multiple Sclerosis Centre, National Centre Hospital, NCNP, Tokyo, Japan Department of Neurology, National Centre Hospital, NCNP, Tokyo, Japan.
  • Araki M; Multiple Sclerosis Centre, National Centre Hospital, NCNP, Tokyo, Japan.
  • Okamoto T; Multiple Sclerosis Centre, National Centre Hospital, NCNP, Tokyo, Japan Department of Neurology, National Centre Hospital, NCNP, Tokyo, Japan.
  • Lin Y; Department of Immunology, National Institute of Neuroscience, National Centre of Neurology and Psychiatry (NCNP), Tokyo, Japan Multiple Sclerosis Centre, National Centre Hospital, NCNP, Tokyo, Japan Department of Neurology, National Centre Hospital, NCNP, Tokyo, Japan.
  • Ogawa M; Multiple Sclerosis Centre, National Centre Hospital, NCNP, Tokyo, Japan Department of Neurology, National Centre Hospital, NCNP, Tokyo, Japan.
  • Murata M; Department of Neurology, National Centre Hospital, NCNP, Tokyo, Japan.
  • Aranami T; Department of Immunology, National Institute of Neuroscience, National Centre of Neurology and Psychiatry (NCNP), Tokyo, Japan Multiple Sclerosis Centre, National Centre Hospital, NCNP, Tokyo, Japan.
  • Yamamura T; Department of Immunology, National Institute of Neuroscience, National Centre of Neurology and Psychiatry (NCNP), Tokyo, Japan Multiple Sclerosis Centre, National Centre Hospital, NCNP, Tokyo, Japan yamamura@ncnp.go.jp.
Mult Scler ; 20(10): 1371-80, 2014 Sep.
Article em En | MEDLINE | ID: mdl-24526661
BACKGROUND: Fingolimod is an oral drug approved for multiple sclerosis (MS) with an ability to trap central memory T cells in secondary lymphoid tissues; however, its variable effectiveness in individual patients indicates the need to evaluate its effects on other lymphoid cells. OBJECTIVE: To clarify the effects of fingolimod on B-cell populations in patients with MS. METHODS: We analysed blood samples from 9 fingolimod-treated and 19 control patients with MS by flow cytometry, to determine the frequencies and activation states of naive B cells, memory B cells, and plasmablasts. RESULTS: The frequencies of each B-cell population in peripheral blood mononuclear cells (PBMC) were greatly reduced 2 weeks after starting fingolimod treatment. Detailed analysis revealed a significant reduction in activated memory B cells (CD38(int-high)), particularly those expressing Ki-67, a marker of cell proliferation. Also, we noted an increased proportion of activated plasmablasts (CD138(+)) among whole plasmablasts, in the patients treated with fingolimod. CONCLUSIONS: The marked reduction of Ki-67(+) memory B cells may be directly linked with the effectiveness of fingolimod in treating MS. In contrast, the relative resistance of CD138(+) plasmablasts to fingolimod may be of relevance for understanding the differential effectiveness of fingolimod in individual patients.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Propilenoglicóis / Esfingosina / Subpopulações de Linfócitos B / Imunossupressores / Esclerose Múltipla Tipo de estudo: Diagnostic_studies / Observational_studies Idioma: En Ano de publicação: 2014 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Propilenoglicóis / Esfingosina / Subpopulações de Linfócitos B / Imunossupressores / Esclerose Múltipla Tipo de estudo: Diagnostic_studies / Observational_studies Idioma: En Ano de publicação: 2014 Tipo de documento: Article